OKUR

OnKure Therapeutics

4.480

+0.280+6.67%

Opening11:48 06/04 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE4.210/4.200

TODAY RANGE4.015-4.550

VOL1.88M

MARKET CAP180.97M

52 WEEK RANGE1.910-5.38

AVG VOL (3M)318.57K

% TURNOVER4.66%

TURNOVER--

P/E (TTM)-1.0354

% RANGE12.74%

EPS(TTM)-4.3269

P/E(FORWARD)-1.1789

P/B0.9817

BVPS4.564

DIVIDEND--

P/S--

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP143.62M

SHARES OUTSTANDING40.40M

NEXT EARNINGS08/10-08/14

FREE FLOAT32.06M

LOT SIZE1

EX-DATE10/07/2024

News

Press Releases

Financial Reports

Profile

NASDAQ·05/22 02:34
Biotech Stock Gainers: CODX Extends Rally, SBFM Surges, GOVX Ebola Strategy, RGNX Awaits Catalysts
TipRanks·05/07 05:57
OnKure Therapeutics downgraded to Hold from Buy at JonesResearch
TipRanks·05/06 12:41
Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), OnKure Therapeutics (OKUR) and Cogent Biosciences (COGT)
TipRanks·05/06 12:31
Analysts Offer Insights on Healthcare Companies: Revvity (RVTY), Option Care Health (OPCH) and OnKure Therapeutics (OKUR)
TipRanks·05/06 12:00
OnKure Therapeutics (OKUR) Receives a Buy from Oppenheimer
TipRanks·05/06 11:16
OnKure Buy Rating Reiterated as Analyst Backs Pipeline Refocus, Strong Cash Position and Maintains $16 Price Target
Seeking Alpha·05/05 21:42
OnKure Therapeutics GAAP EPS of -$1.11 misses by $0.37
Dow Jones·05/05 20:41
*OnKure Therapeutics 1Q Loss $15.2M >OKUR
PUBT·05/05 20:09
OnKure net loss narrows to $15.2 million in Q1 2026
TipRanks·04/24 20:12
OnKure Therapeutics files to sell 36.14M shares of Class A common for holders
PUBT·04/21 20:19
OnKure Therapeutics announces annual shareholder meeting notice
Reuters·04/08 01:15
OnKure Therapeutics initial beneficial ownership filing names AI Biotechnology LLC as 10% owner
TipRanks·04/06 20:38
OnKure Therapeutics (OKUR) Gets a Buy from JonesTrading
Reuters·04/01 21:24
OnKure Therapeutics files Form 3; director Liam Ratcliffe reports no beneficial ownership
Reuters·03/30 11:16
ONKURE THERAPEUTICS INC <OKUR.O>: LEERINK PARTNERS CUTS TARGET PRICE TO $11 FROM $29

Same Industry

Name/Symbol

Change%

Price

OnKure Therapeutics

OKUR

+6.67%

4.480

REGN

GridAI Tech

GRDX

+13.33%

5.61

BNTX

United Therapeutics Corp.

UTHR

-0.94%

556.82

Vertex Pharmaceuticals Inc

VRTX

-0.10%

447.54

Siga Technologie

SIGA

-1.68%

4.680

Moderna

MRNA

-0.80%

47.19

Charles Riv Labs Intl Inc

CRL

-4.00%

174.79

Medpace Holdings

MEDP

-0.23%

447.11

TLPH

ICON plc

ICLR

-0.53%

136.07

China Biologic

CBPO

0.00%

119.99

Iqvia Hldgs Inc

IQV

-0.71%

185.50

MOLECULAR PARTNERS AG

MOLN

+4.92%

4.200

Arcturus Therape

ARCT

-3.15%

7.53

Gilead Sciences Inc

GILD

-1.31%

134.43

PRAH

Incyte Corp

INCY

-1.98%

93.70

APVO

BSTC

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.